45 CFR § 180 compliance
C · 70
This hospital published part of what § 180 requires.
●Machine-readable file published
○Gross / standard charges
○Discounted cash price
●Payer-specific negotiated rates
●Min / max negotiated charges
●Free, public, no login required
Procedures listed
11,504
Insurances with rates
8
CPT / HCPCS codes
10,463
Source MRF
Most expensive procedures (gross)
| Code | Description | Gross | Cash | Min payer | Max payer | # insurers |
|---|---|---|---|---|---|---|
| J9228 | IPILIMUMAB 200 MG/40 ML (5 MG/ML) INTRAVENOUS SOLUTION | $211,865 | $77,644 | $192,797 | $192,797 | 1 |
| J9228 | IPILIMUMAB 200 MG/40 ML (5 MG/ML) INTRAVENOUS SOLUTION | $211,865 | $77,644 | $172 | $192,797 | 22 |
| J2350 | OCRELIZUMAB 30 MG/ML INTRAVENOUS SOLUTION | $115,156 | $42,203 | $104,792 | $104,792 | 1 |
| J2350 | OCRELIZUMAB 30 MG/ML INTRAVENOUS SOLUTION | $115,156 | $42,203 | $56.14 | $104,792 | 22 |
| J0638 | CANAKINUMAB (PF) 150 MG/ML SUBCUTANEOUS SOLUTION | $110,813 | $40,611 | $100,840 | $100,840 | 1 |
| J0638 | CANAKINUMAB (PF) 150 MG/ML SUBCUTANEOUS SOLUTION | $110,813 | $40,611 | $133 | $100,840 | 22 |
| J9309 | POLATUZUMAB VEDOTIN-PIIQ 140 MG INTRAVENOUS SOLUTION | $102,938 | $37,725 | $93,674 | $93,674 | 1 |
| J9309 | POLATUZUMAB VEDOTIN-PIIQ 140 MG INTRAVENOUS SOLUTION | $102,938 | $37,725 | $128 | $93,674 | 22 |
| J3357 | USTEKINUMAB 45 MG/0.5 ML SUBCUTANEOUS SYRINGE | $80,111 | $29,359 | $72,901 | $72,901 | 1 |
| J3357 | USTEKINUMAB 45 MG/0.5 ML SUBCUTANEOUS SYRINGE | $80,111 | $29,359 | $148 | $72,901 | 22 |
| J9042 | BRENTUXIMAB VEDOTIN 50 MG INTRAVENOUS SOLUTION | $66,619 | $24,415 | $60,623 | $60,623 | 1 |
| J9042 | BRENTUXIMAB VEDOTIN 50 MG INTRAVENOUS SOLUTION | $66,619 | $24,415 | $243 | $60,623 | 22 |
| J9022 | ATEZOLIZUMAB 1200 MG/20 ML (60 MG/ML) INTRAVENOUS SOLUTION | $65,111 | $23,862 | $59,251 | $59,251 | 1 |
| J9022 | ATEZOLIZUMAB 1200 MG/20 ML (60 MG/ML) INTRAVENOUS SOLUTION | $65,111 | $23,862 | $85.58 | $59,251 | 22 |
| J9119 | CEMIPLIMAB-RWLC 50 MG/ML INTRAVENOUS SOLUTION | $63,539 | $23,286 | $57,820 | $57,820 | 1 |
| J9119 | CEMIPLIMAB-RWLC 50 MG/ML INTRAVENOUS SOLUTION | $63,539 | $23,286 | $26.98 | $57,820 | 22 |
| C2642 | GAMMATILE THERAPY 11PK GT-11 | $57,820 | $21,190 | $52,616 | $52,616 | 1 |
| C2642 | GAMMATILE THERAPY 11PK GT-11 | $57,820 | $21,190 | $101 | $52,616 | 20 |
| J9144 | DARATUMUMAB 1800 MG-HYALURONIDASE-FIHJ 30000 UNIT/15 ML SUBCUT SOLN | $57,439 | $21,050 | $52,270 | $52,270 | 1 |
| J9144 | DARATUMUMAB 1800 MG-HYALURONIDASE-FIHJ 30000 UNIT/15 ML SUBCUT SOLN | $57,439 | $21,050 | $51.4 | $52,270 | 22 |
| J9037 | BELANTAMAB MAFODOTIN-BLMF 100 MG INTRAVENOUS SOLUTION | $55,590 | $20,373 | $50,587 | $50,587 | 1 |
| J9037 | BELANTAMAB MAFODOTIN-BLMF 100 MG INTRAVENOUS SOLUTION | $55,590 | $20,373 | $11,635 | $50,587 | 15 |
| J2997 | ALTEPLASE 100 MG INTRAVENOUS SOLUTION | $52,285 | $19,161 | $47,579 | $47,579 | 1 |
| J2997 | ALTEPLASE 100 MG INTRAVENOUS SOLUTION | $52,285 | $19,161 | $88.53 | $47,579 | 22 |
| J3380 | VEDOLIZUMAB 300 MG INTRAVENOUS SOLUTION | $50,085 | $18,355 | $45,577 | $45,577 | 1 |
| J3380 | VEDOLIZUMAB 300 MG INTRAVENOUS SOLUTION | $50,085 | $18,355 | $20.74 | $45,577 | 22 |
| J1930 | LANREOTIDE 120 MG/0.5 ML SUBCUTANEOUS SYRINGE | $48,444 | $17,754 | $44,084 | $44,084 | 1 |
| J1930 | LANREOTIDE 120 MG/0.5 ML SUBCUTANEOUS SYRINGE | $48,444 | $17,754 | $34.47 | $44,084 | 22 |
| 0795T | TCAT INS 2CHMBR LDLS PM CMPL | $48,321 | $17,709 | $43,972 | $43,972 | 1 |
| 0795T | TCAT INS 2CHMBR LDLS PM CMPL | $48,321 | $17,709 | $10,114 | $43,972 | 13 |
| 0796T | TCAT INS 2CHMBR LDLS PM RA | $48,321 | $17,709 | $43,972 | $43,972 | 1 |
| 0796T | TCAT INS 2CHMBR LDLS PM RA | $48,321 | $17,709 | $10,114 | $43,972 | 13 |
| 0797T | TCAT INS 2CHMBR LDLS PM RV | $48,321 | $17,709 | $43,972 | $43,972 | 1 |
| 0797T | TCAT INS 2CHMBR LDLS PM RV | $48,321 | $17,709 | $10,114 | $43,972 | 13 |
| 0801T | TCAT RMV&RPL 2CHMBR LDLS PM | $48,321 | $17,709 | $43,972 | $43,972 | 1 |
| 0801T | TCAT RMV&RPL 2CHMBR LDLS PM | $48,321 | $17,709 | $10,114 | $43,972 | 13 |
| 0802T | TCAT RMV&RPL2CHMB LDLS PM RA | $48,321 | $17,709 | $43,972 | $43,972 | 1 |
| 0802T | TCAT RMV&RPL2CHMB LDLS PM RA | $48,321 | $17,709 | $10,114 | $43,972 | 13 |
| 0803T | TCAT RMV&RPL2CHMB LDLS PM RV | $48,321 | $17,709 | $43,972 | $43,972 | 1 |
| 0803T | TCAT RMV&RPL2CHMB LDLS PM RV | $48,321 | $17,709 | $10,114 | $43,972 | 13 |
| J9223 | LURBINECTEDIN 4 MG INTRAVENOUS SOLUTION | $47,756 | $17,502 | $43,458 | $43,458 | 1 |
| J9223 | LURBINECTEDIN 4 MG INTRAVENOUS SOLUTION | $47,756 | $17,502 | $194 | $43,458 | 22 |
| J9301 | OBINUTUZUMAB 1000 MG/40 ML INTRAVENOUS SOLUTION | $47,423 | $17,380 | $43,155 | $43,155 | 1 |
| J9301 | OBINUTUZUMAB 1000 MG/40 ML INTRAVENOUS SOLUTION | $47,423 | $17,380 | $73.77 | $43,155 | 22 |
| C9765 | REVASC INTRA LITHOTRIP-STENT | $45,091 | $16,525 | $41,033 | $41,033 | 1 |
| C9765 | REVASC INTRA LITHOTRIP-STENT | $45,091 | $16,525 | $9,438 | $41,033 | 20 |
| C9766 | REVASC INTRA LITHOTRIP-ATHER | $45,091 | $16,525 | $41,033 | $41,033 | 1 |
| C9766 | REVASC INTRA LITHOTRIP-ATHER | $45,091 | $16,525 | $9,438 | $41,033 | 20 |
| C9767 | REVASC LITHOTRIP-STENT-ATHER | $45,091 | $16,525 | $41,033 | $41,033 | 1 |
| C9767 | REVASC LITHOTRIP-STENT-ATHER | $45,091 | $16,525 | $9,438 | $41,033 | 20 |
Showing top 50 of 11,504 priced procedures, sorted by gross charge.
Data straight from this hospital's federally-mandated machine-readable file (45 CFR § 180). The compliance grade reflects how completely the hospital published the six required data elements, not the quality of care.